89 related articles for article (PubMed ID: 17674606)
1. What happened to the Provenge (Sipuleucel-T) vaccine for hormone refractory prostate cancer?
Moyad MA
Urol Nurs; 2007 Jun; 27(3):256-7. PubMed ID: 17674606
[TBL] [Abstract][Full Text] [Related]
2. Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention.
Jarosławski S; Toumi M
BioDrugs; 2015 Oct; 29(5):301-7. PubMed ID: 26403092
[TBL] [Abstract][Full Text] [Related]
3. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.
Cheever MA; Higano CS
Clin Cancer Res; 2011 Jun; 17(11):3520-6. PubMed ID: 21471425
[TBL] [Abstract][Full Text] [Related]
4. Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.
Madan RA; Gulley JL
Expert Rev Vaccines; 2011 Feb; 10(2):141-50. PubMed ID: 21332262
[TBL] [Abstract][Full Text] [Related]
5. Listening to Provenge--what a costly cancer treatment says about future Medicare policy.
Chambers JD; Neumann PJ
N Engl J Med; 2011 May; 364(18):1687-9. PubMed ID: 21470004
[No Abstract] [Full Text] [Related]
6. The Provenge decision.
DeVita VT
Nat Clin Pract Oncol; 2007 Jul; 4(7):381. PubMed ID: 17554239
[No Abstract] [Full Text] [Related]
7. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
McKarney I
Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
[TBL] [Abstract][Full Text] [Related]
8. Approval of provenge seen as first step for cancer treatment vaccines.
Brower V
J Natl Cancer Inst; 2010 Aug; 102(15):1108-10. PubMed ID: 20668267
[No Abstract] [Full Text] [Related]
9. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.
Patel PH; Kockler DR
Ann Pharmacother; 2008 Jan; 42(1):91-8. PubMed ID: 18094343
[TBL] [Abstract][Full Text] [Related]
10. Provenge: revolutionary technology or ethical bust?
Dickerson JB
Hum Vaccin; 2011 Apr; 7(4):477-80. PubMed ID: 21451262
[TBL] [Abstract][Full Text] [Related]
11. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.
Thara E; Dorff TB; Pinski JK; Quinn DI
Maturitas; 2011 Aug; 69(4):296-303. PubMed ID: 21621934
[TBL] [Abstract][Full Text] [Related]
12. Sipuleucel-T (APC8015) for prostate cancer.
So-Rosillo R; Small EJ
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1163-7. PubMed ID: 17020451
[TBL] [Abstract][Full Text] [Related]
13. Sipuleucel-T: a therapeutic cancer vaccine for the treatment of castration- or hormone-refractory prostate cancer.
Bulloch MN; Elayan MM; Renfroe HR
Expert Rev Clin Pharmacol; 2011 Nov; 4(6):685-92. PubMed ID: 22111853
[TBL] [Abstract][Full Text] [Related]
14. Concerns about Provenge simmer as CMS ponders coverage.
Goozner M
J Natl Cancer Inst; 2011 Feb; 103(4):288-9. PubMed ID: 21303996
[No Abstract] [Full Text] [Related]
15. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
Small EJ; Schellhammer PF; Higano CS; Redfern CH; Nemunaitis JJ; Valone FH; Verjee SS; Jones LA; Hershberg RM
J Clin Oncol; 2006 Jul; 24(19):3089-94. PubMed ID: 16809734
[TBL] [Abstract][Full Text] [Related]
16. Dendreon vs CMS: why the Provenge coverage controversy is bigger than just one product.
Baghdadi R
Oncology (Williston Park); 2010 Sep; 24(10):881-3. PubMed ID: 21138168
[No Abstract] [Full Text] [Related]
17. Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer.
Peppercorn J; Armstrong A; Zaas DW; George D
Urol Oncol; 2013 Oct; 31(7):1079-84. PubMed ID: 22305627
[TBL] [Abstract][Full Text] [Related]
18. Current vaccination strategies for prostate cancer.
Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
[TBL] [Abstract][Full Text] [Related]
19. The role of complement in dendritic cell (DC) control of T-cell subsets.
Levis WR; Martiniuk F
J Drugs Dermatol; 2010 Nov; 9(11):1364-6. PubMed ID: 21061758
[TBL] [Abstract][Full Text] [Related]
20. Abigail Alliance v. Von Eschenbach: restricting access to potentially lifesaving drugs singe 2007.
Goodman AJ
J Contemp Health Law Policy; 2008; 25(1):107-41. PubMed ID: 19137749
[No Abstract] [Full Text] [Related]
[Next] [New Search]
